METiS Therapeutics

METiS Therapeutics is a drug discovery company focused on developing small molecule and ribonucleic acid (RNA) therapeutics targeting various serious diseases. 

The company’s drug discovery and delivery platform “AiTEM” leverages technologies such as AI, machine learning, and quantum simulation to expedite the drug discovery and development process through faster lead optimization, candidate selection, and formulation design. 

Metis Therapeutics’ internal drug pipeline will initially focus on orphan diseases, central nervous system (CNS) disease, and autoimmune diseases, and includes advanced lipid nanoparticles (LNPs). 

Key customers and partnerships

The company has several key partners for product development. These include 1) Evopoint Biosciences to develop and commercialize Evopoint’s SOS1 inhibitor program ( January 2023 ) and 2) Voronoi to develop and commercialize Voronoi’s pan-RAF inhibitor program ( September 2022 ). 

Funding and financials

In April 2022 , METiS Therapeutics raised USD 64 million in a Series A-2 funding round led by PICC Capital and China Life Private Equity Investment, bringing the total Series A funds to USD 150 million (the previous Series A round closed in December 2021 ). The funds were directed toward accelerating the company’s R&D efforts, including the development of its platform and advancing a few of its drug candidates into clinical trials.